Tumors contain the seeds of their own destruction. We just need to work out how to activate them.
So far, few patients have received the new drugs, as commercial health plans and Medicare wrestle with how to cover the treatment.
Like the diamondback moth, cancer cells develop resistance to the powerful chemicals deployed to destroy them. Even if cancer therapies kill most of the cells they target, a small subset can survive, largely thanks to genetic changes that render them resistant.
Precision medicine should become more widely available, and fewer patients will need to travel far for care.
“The system for caring for cancer survivors in the U.S. we have currently is not sustainable. We have more survivors and they are living longer, which is, of course, wonderful, but healthcare systems are not currently set up to care for a large and increasing number of survivors,” said Leach.
Researchers explore leaner approaches aimed at sparing patients tough side effects—and costs.
OF ALL THE cancers in the world, lung cancer is the deadliest. This year, the National Cancer Institute estimates it will kill 150,000 people, despite a growing number of more targeted therapies. But that could all soon change. On Thursday, the Food and Drug Administration approved the first next-generation-sequencing-based test, from Thermo Fisher Scientific, that can tell you how different drugs will work for you, based on the genetic makeup of your tumor. And it only takes four days to get back results.
A new law requiring pharmaceuticals companies to test cancer drugs on children as well as adults is raising hopes of more therapies.
Carl June, a pioneer in the field of immunotherapy, explains the state of the art in cancer treatment and what’s coming next.
Understanding how the disease evolves is the key to stopping it.
The holdup, he thought, would be finding patients. Instead, the real impediment turned out to be gathering their medical records.
In the United States, there is no single format used by all providers, and hospitals have no incentive to make it easy to transfer records from one place to another. The medical records mess is hobbling research and impeding attempts to improve patient care.
The point is that precision medicine is not just precision mutant-hunting. It may be decidedly low-tech and may apply to conditions other than cancer.
Researchers recently announced that many women diagnosed with breast cancer might be able to skip chemo. A group of doctors argued the same, half a century ago—and were ridiculed.
I understand that, particularly in this age of breathtakingly expensive cancer treatment, there is a need for checks and balances on our treatment recommendations and their potential benefit. That public health perspective seemed awfully shortsighted, though, when I had to face my patient and his dad each week as his leukemia threatened to come raging back.
Cancer is not a death sentence; there is a great deal of difference between a prostate and a pancreatic cancer diagnosis, and even differences between subtypes of cancer within any particular organ. Recent statistics on cancer survival rates are instructive...
I believe in treating cancer with anything that works. Show me that something works, and I’ll use it. Period.
But don’t give me a story of how someone’s aunt’s best friend was told that she had six months to live and was cured by taking a natural supplement found through the Internet and is still alive 10 years later—and then ask me to give the OK to try it.
“When I was taking care of my aunt, I was like, There must be something better than just dying like this."
Tumours are subject to the same rules of natural selection as any other living thing. Clinicians are now putting that knowledge to use.
Memorial Sloan Kettering scientists and doctors firmly believe we're on the cusp of a brighter era in cancer care and research. Although the history of attempts to understand and control cancer is littered with disappointments, many significant advances in research and treatment have been made in recent years. Despite the challenges, we now have more reasons than ever to be hopeful. These are five of them.
Cancer is becoming more common across Africa, but the continent’s doctors and policy makers are barely equipped to provide adequate treatment. New cancer cases are expected to double by 2030 to around 1.3 million, according to an American Cancer Society (ACS) study (PDF). If national cancer treatment strategies aren’t fixed, only 10% of patients will receive treatment, including basic pain medication.
Adult stem cells hold enormous potential in the treatment of disease, but more importantly they do not carry the burden of controversy that has surrounded embryonic stem cells for well over two decades.
Boston pharma startup Berg uses an AI to analyse terabytes of cancer data. It's a radical approach, but it may just work.
Cancer’s most promising therapies come with $100,000-plus price tags.
Being burdened with cancer is challenging without the resources needed to make informed decisions. Let us bring you to the forefront of clinical science and facilitate faster access to advanced treatment options that are beyond the standard of care.
We have all heard about the extraordinary promise that stem cell research holds for the treatment of human diseases. Clinics all over the world claim to offer stem cell treatments for a wide variety of conditions. But are all of these treatments likely to be safe and effective?
The ISSCR provides information to help you evaluate these claims.
Springboard Beyond Cancer was developed by the National Cancer Institute and the American Cancer Society (link is external). This web tool reflects their shared mission of getting health information, skills, and support to the people whose lives are affected by cancer.
For people with life-threatening blood cancers like leukemia and lymphoma or other diseases, a cure exists. Be The Match® connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant.
CTCA provides cancer treatment using new, innovative and traditional cancer treatments: some of which involve the use of stem cells. Many patients choose to come to CTCA because they believe in our integrative approach to cancer treatment.